Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687107 | 0.95 | PDE4A (0.47) | PDE4ALMNAL3MBTL1PGDTDP1 | |
| SCHEMBL536485 | 0.95 | PDE4A (0.47) | PDE4ALMNAL3MBTL1PGDTDP1 | |
| SCHEMBL4314209 | 0.91 | PDE4A (0.36) | PDE4ALMNAL3MBTL1PGDTDP1 | |
| Demannose SCHEMBL4340605 | 0.85 | PDE4A (0.39) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL10699708 | 0.81 | USP2 (0.50) | PDE4ALMNAL3MBTL1PGDTDP1 | |
| SCHEMBL8582227 | 0.81 | LMNA (0.37) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL8580151 | 0.81 | LMNA (0.37) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL3350436 | 0.78 | PDE4A (0.46) | PDE4ALMNAL3MBTL1PGDTDP1 | |
| Fructose SCHEMBL5454022 | 0.78 | CYP2C9 (0.44) | PDE4ALMNAL3MBTL1PGDTDP1 | |
| Fructose SCHEMBL5418705 | 0.78 | CYP2C9 (0.44) | PDE4ALMNAL3MBTL1PGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250347698-A1 | Multi-Omics Biomarker Detection System and Methods for Disease Diagnostics | COMPLETE OMICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12370209-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4463232-A1 | SOLID STATE FORMS OF RUCAPARIB TOSYLATE | Assia Chemical Industries Ltd. (IL) | 2024-11-20 | — | — | EP | disclosed |
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | DISARM THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240180892-A1 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | IMMUNOMEDICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240091249-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230338521-A1 | METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, A CHEMORADIATION THERAPY AND A PARP INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20070298998-A1 | Biomarkers for amyotrophic lateral sclerosis and methods using the same | METABOLON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-20070078100-A1 | Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2005038043-A2 | METHODS OF DETECTING POLY (ADP-RIBOSE) POLYMERASE AND OTHER NAD+UTILIZING ENZYMES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1458688-A1 | QUINAZOLINONE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | disclosed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | disclosed |
| CN-1345733-A | Novel polypeptide-protein 11.55 containing polyadenylic diphosphoribose and polynucleotide for encoding said polypeptide | SHANGHAI BIOWINDOW GENE DEV (CN) | 2002-04-24 | — | — | CN | disclosed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370209-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | PDE4A 230/4885LMNA 933/4885L3MBTL1 3327/4885 |
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | SARM1, SMN1; SMN2, SARNP | PDE4A 2766/4885LMNA 1527/4885L3MBTL1 696/4885 |
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | PDE4A 230/4885LMNA 933/4885L3MBTL1 3327/4885 |
| US-20070078100-A1 | Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes | PARP1, PARP11, PARP3 | PDE4A 1185/4885LMNA 755/4885L3MBTL1 2509/4885 |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | PDE4A 1698/4885LMNA 674/4885L3MBTL1 3505/4885 |
| US-20240091249-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | ADAR, CD38, PARP1 | PDE4A 230/4885LMNA 942/4885L3MBTL1 3360/4885 |
| US-20230338521-A1 | METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, A CHEMORADIATION THERAPY AND A PARP INHIBITOR | PARP1, PDCD1, PARP2 | PDE4A 1538/4885LMNA 1085/4885L3MBTL1 1641/4885 |
| US-20240180892-A1 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | PARP2, CD22, DOCK2 | PDE4A 1326/4885LMNA 3708/4885L3MBTL1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.